Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case Report.

ABSTRACT:

Introduction

Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has become a standard treatment option for metastatic urothelial carcinoma (mUC) following failure of platinum-based chemotherapy and immune checkpoint inhibitors. However, adverse events (AEs) such as skin toxicity often necessitate dose modification or temporary discontinuation.

Case presentation

We report the case of a 72-year-old woman with mUC who achieved a long-term partial response to EV despite experiencing grade 2 skin toxicity that required temporary treatment interruption. After symptom resolution, EV was successfully reintroduced at a reduced dose, and clinical response was maintained.

Conclusion

Temporary discontinuation of EV due to AEs followed by intermittent reintrod

SUBMITTER: Fujii K 

PROVIDER: S-EPMC12755892 | biostudies-literature | 2026 Jan-Dec

REPOSITORIES: biostudies-literature